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Abstract
Background: Stress-related disorders involve systemic alterations, including disruption of the intestinal microbial
community. Given the putative connections between the microbiota, immunity, neural function, and behaviour,
we investigated the potential for microbe-induced gut-to-brain signalling to modulate the impact of stress on host
behaviour and immunoregulation.
Methods: Male C57BL/6 mice treated orally over 28 days with either Lactobacillus rhamnosus (JB-1) ™ or vehicle
were subjected to chronic social defeat and assessed for alterations in behaviour and immune cell phenotype.
16S rRNA sequencing and mass spectrometry were employed to analyse the faecal microbial community and
metabolite profile.
Results: Treatment with JB-1 decreased stress-induced anxiety-like behaviour and prevented deficits in social
interaction with conspecifics. However, JB-1 did not alter development of aggressor avoidance following social defeat.
Microbial treatment attenuated stress-related activation of dendritic cells while increasing IL-10+ regulatory T cells.
Furthermore, JB-1 modulated the effect of stress on faecal metabolites with neuroactive and immunomodulatory
properties. Exposure to social defeat altered faecal microbial community composition and reduced species richness
and diversity, none of which was prevented by JB-1.
Stress-related microbiota disruptions persisted in vehicle-treated mice for 3 weeks following stressor cessation.
Conclusions: These data demonstrate that despite the complexity of the gut microbiota, exposure to a single
microbial strain can protect against certain stress-induced behaviours and systemic immune alterations without
preventing dysbiosis. This work supports microbe-based interventions for stress-related disorders.
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Background
Stress-related disorders have their roots in nuanced in-
teractions between genetic and environmental risk fac-
tors, resulting in complex and multifactorial etiologies.
The cumulative physiological effect of stressors [1]
causes the dysregulation of multiple host systems due to
allostatic overload. The last decade has witnessed a grow-
ing interest in the potential contribution of gut-brain sig-
nalling to psychiatric disorders. Chronic severe stress is
associated with inflammation and increased susceptibility
to functional gastrointestinal conditions, and there is
strong evidence for co-morbidity between gastrointestinal
symptoms and psychiatric disorders [2–4]. Although pre-
cise biological mechanisms remain unclear, it is possible
that such bidirectional associations in stress are at least
partly a consequence of alterations in gut-brain signalling
pathways due to a disrupted gut microbial community.
The latter is complex and dynamic, harbouring ~1013
* Correspondence: forsytp@mcmaster.ca
2McMaster Brain-Body Institute, The Research Institute of St. Joseph’s
Hamilton, Hamilton, Canada
4Department of Medicine, McMaster University, The Brain-Body Institute, 50
Charlton Avenue East, T3302, Hamilton, Ontario L8N 4A6, Canada
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bharwani et al. BMC Medicine  (2017) 15:7 
DOI 10.1186/s12916-016-0771-7
bacterial cells that represent 3.3 million non-redundant
genes, rivalling our human genome by at least two orders
of magnitude [5]. The critical role of the gut microbial
community in the regulation of diverse physiological func-
tions, including immunity, is well established, and there is
growing evidence of its influence on the central nervous
system [6–8]. For instance, administration of specific bac-
terial strains decreases anxiety- and depressive-like behav-
iours [9, 10], while changes in the microbial community
modulate stress-induced inflammation [11, 12]. The
emergent corollary demonstrates the inextricable rela-
tionship between the microbiota, immune, and nervous
systems, and their roles in regulating behaviour and
neural function. Indeed, along with other groups, we
have demonstrated the top-down effect of psychological
stress on the structure and function of the microbiota,
resulting in reduced species diversity and richness, an
altered community profile, and shifts in functional
pathways [12–14]. Given microbial regulation of host
signalling at the mucosal interface between microbiota
and host, disruptions in this community may lead to
systemic changes in peripheral signals [15, 16]. For
instance, immune dysregulation has been implicated
in psychological stressors and psychiatric disorders
[12, 17]. However, much remains to be determined
regarding how bottom-up signalling along the gut-
brain axis might be utilized to modulate stress-related
changes in behaviour and neural function.
The aim of the present study was to investigate the
role of microbe-induced gut-to-brain signalling on the
central and systemic disruptions induced by chronic ex-
posure to a psychosocial stressor. Using a validated
model of chronic stress and depression [18, 19], we de-
termined whether oral administration of a bacterium
with neuroactive and immunomodulatory properties
could modulate stress-induced behavioural deficits, im-
mune changes, and gut dysbiosis. We selected Lactoba-
cillus rhamnosus JB-1TM (JB-1) as our test organism, as
oral treatment with this strain was previously demon-
strated to lead to changes in neurotransmitter levels in
the brains of mice [20] and to have anxiolytic and anti-
depressant-like activity on baseline behaviours—effects
dependent on an intact vagus nerve [10]. Feeding the JB-
1 strain also modulates enteric nervous system function
[21], increases the frequency of vagal afferent firing [22],
and has well-described anti-inflammatory and immuno-
regulatory effects [23–25]. To elucidate metabolites that
may drive effects of bacteria on the brain, we investi-
gated candidate functional pathways using metabolomics
profiling. Furthermore, we examined the duration of
stress-induced disruptions in the microbiota and the
possibility of whether administration of a single bacterial




Male C57BL/6 mice, 8 weeks old, and CD-1 retired
breeders were acquired from Charles River (Montreal,
Canada). Animals were acclimatized for 7 days in stand-
ard conditions (12-h light-dark cycle) with ad libitum
access to standard chow and water. All experiments
followed Canadian Council on Animal Care guidelines
and were approved by the McMaster Animal Research
Ethics Board.
Treatment and social defeat
Animals were gavaged with 200 μl (1.67 × 109 CFU) of
Lactobacillus rhamnosus (JB-1) ™—a gift from Alimen-
tary Health Ltd., Cork, Ireland—or equivalent volume of
phosphate-buffered saline (PBS). Treatment was admin-
istered over 28 days, Monday to Friday, between 1 to
3 p.m. During the final 10 days of treatment (Fig. 1),
chronic social defeat (CSD) was initiated as previously
described (Additional file 1) [18]. For 24 h after each
defeat, mice were housed in the same cage across a per-
forated Plexiglas divider from their aggressors.
Behavioural testing
Details of the behavioural testing are provided in
Additional file 1. Behavioural testing began 24 h after
the final defeat session, and was recorded/analysed using
Motor Monitor (Kinder Scientific) and EthoVision XT
(Noldus). Anxiety-like and exploratory behaviours were
assessed using the light-dark box test (LDT) and open
field test (OFT). Sociability and susceptibility were
assessed using the three-chamber sociability and aggres-
sor approach-avoidance tests.
Tissue analysis
Mice were euthanized 5 days after the final defeat ses-
sion. Spleens were harvested and dispersed using a cell
strainer in cold, sterile PBS. Cell suspensions were
centrifuged at 1500 rpm for 10 min at 4 °C, then re-
suspended in red blood cell (RBC) lysis buffer for 1–
2 min. The resulting solution was centrifuged before the
cell pellets were washed with 5 ml of complete RPMI
1640 medium: 10% foetal bovine serum, penicillin/
streptomycin antibiotics, 2 mM L-glutamine, and 0.01%
β-mercaptoethanol. Viable cell numbers were assessed
by Trypan Blue exclusion and diluted in RPMI to a con-
centration of 107 cells/ml. Splenocytes (106) were stained
for markers of dendritic cell (DC) maturation and
function—CD11c- PerCP-Cy5, MHCII-FITC, CD80-PE,
and CD86-APC—or regulatory T cells—CD3-APC, CD4-
FITC, CD25-PE-Cy7, and intracellular IL-10-PE (BD
Pharmingen, San Diego, CA, USA; eBioscience, San
Diego, CA, USA). Following surface staining, cells were
fixed and permeabilized with BD Cytofix/Cytoperm
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before staining for intracellular markers. Data were
acquired with FACSCanto (Becton Dickinson, Oakville,
ON, Canada) and analysed using FlowJo (TreeStar,
Ashland, OR, USA).
RNA extraction and RT-qPCR analyses
Following rapid decapitation, the frontal cortex and
hippocampus were macrodissected using their stereo-
taxic coordinates according to the Mouse Brain Atlas
and placed into RNAlater® solution (Ambion, Life Tech-
nologies, CA, USA). Tissues were incubated overnight at
4 °C and then transferred to –20 °C storage to await fur-
ther processing. RNA extraction was carried out using
TRIzol® Reagent (Ambion, Life Technologies) following
manual homogenization. RNA quality was assessed
using a NanoDrop® Spectrophotometer ND-1000. 1 μg
RNA was then converted into complementary DNA
(cDNA) by using SuperscriptIII™ First-Strand Synthesis
Supermix (Invitrogen, CA, USA). Diluted or non-diluted
cDNA was used as a template for qPCR reaction using
PowerUp™ SYBR®Green Master Mix (Applied Biosys-
tems, Life Technologies, Austin, TX, USA) containing
ROX™ Passive Reference Dye. The qPCR reactions were
performed in the fast mode (uracil-DNA glycosylase
[UDG] activation 50 °C, 2 min; Dual-Lock™ DNA poly-
merase 95 °C, 2 min; denaturation 95 °C, 1 s; annealing/
extension 60 °C, 30 s; number of cycles: 40) by using
QuanStudio3™ (Applied Biosystems). Primers were de-
signed with Primer Express™ Software and used at a con-
centration of 300 nM. Primer sequences are listed in
Additional file 2: Table S6. Transcripts were normalized
to endogenous glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) and quantified using the ΔΔCt method,
with related fold change expressed as 2(-ΔΔCt)
16S rRNA analysis and metabolomics
Faecal pellets were stored at –80 °C. DNA extraction
was carried out as previously described [13]. Bacterial
community profiling of 16S rRNA was carried out on a
MiSeq Illumina sequencer in the McMaster Genome
Center (McMaster University). Metabolite profiling was
performed by Metabolon, Inc.
Using rarefied data in QIIME [26], Chao1 and phylo-
genetic diversity metrics were implemented, and
Jackknife resampling was used to generate Bray-Curtis
distances. (Dis)similarity between the groups was calcu-
lated using the Monte Carlo permutation procedure
(MCPP) (999 permutations) and a priori Bonferroni-
corrected non-parametric t tests. Kruskal-Wallis one-way
analysis of variance (ANOVA) or the Mann-Whitney U
test, followed by the Benjamini-Hochberg correction for
multiple comparisons (false discovery rate, FDR < 0.05),
was used to analyse differential abundance of operational
taxonomic units (OTUs) in groups.
Statistical analysis
Data were analysed in IBM’s SPSS (version 22,
Chicago) and GraphPad Prism 6 using a two-tailed Stu-
dent’s t test, Mann-Whitney U test, or ANOVAs, with
Bonferroni-corrected post hoc tests. Two-way ANO-
VAs with contrasts followed by Benjamini-Hochberg
correction (FDR <0.1) were used to analyse metabolo-
mics data. No statistical methods were used to prede-
termine sample sizes; however, n values used herein are
consistent with previous work. During the course of so-
cial defeat and testing, some animals were removed
due to excessive wounding (open wounds exceeding
1 cm, as per the Animal Utilization Protocol approved
by McMaster’s Animal Research Ethics Board). Results
in figures are expressed as mean ± standard error of the
Fig. 1 Schematic diagram of experimental approach. Mice were treated with JB-1 on 20 instances over a period of 28 days, including 7 instances
over the final 10 days, during which mice were exposed to chronic social defeat (CSD) stress every day. OFT open field test, LDT light-dark box test
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mean (SEM), where applicable. Statistical significance is
denoted as * (p < 0.05), ** (p < 0.01), and *** (p < 0.001).
Results
Microbial treatment modulates specific stress-induced
behavioural deficits
Chronic social defeat (CSD) reveals distinct phenoty-
pes—susceptible and resilient—based on behaviour in
the aggressor approach-avoidance test [18, 19, 27]. CSD
induced expression of both phenotypes in either treat-
ment group, with no difference in the proportion of re-
silient mice: 18.1% (6/33) of vehicle-treated defeated
mice and 15.6% (5/32) of defeated mice treated with JB-
1 until CSD cessation. Only the susceptible group was
used for all experiments.
We have previously demonstrated that mice subjected
to CSD exhibit sociability deficits [13]. Vehicle-treated
defeated mice (DEF/VEH) exhibited pronounced avoid-
ance of the social chamber (group × chamber interaction
[F1, 23 = 5.438, p = 0.029, post hoc, p < 0.05]) (Fig. 2b).
However, defeated mice administered JB-1 (DEF/JB-1)
demonstrated no preference between the social and
non-social chambers (post hoc, p > 0.05) (Fig. 2b) and,
relative to DEF/VEH, exhibited a greater social:non-so-
cial ratio (F1, 39 = 9.660, p = 0.004, post hoc, p < 0.05)
(Fig. 2c), indicating a partial correction of stress-induced
deficits in social behaviour. Notably, treatment did not
alter baseline behaviour (Fig. 2a).
Susceptible mice markedly avoid interactions with a
novel aggressor [18]. Thus, we investigated whether the
positive effects of JB-1 extended to behaviour on the ag-
gressor approach-avoidance test (Fig. 2d). DEF/JB-1 mice
continued to exhibit pronounced avoidance of the zone
surrounding the aggressor (‘interaction zone’) exclusively
during the presence of the aggressor (F1, 23 = 130.8,
p < 0.0001) (Fig. 2e).
Chronic social stress also induces anxiety-like behaviour
and deficits in exploration [13, 28]. On the OFT, stress de-
creased rearing behaviour (F1, 81 = 131.2, p < 0.0001), indi-
cating reduced exploration. Simple effects analysis of
defeated groups revealed that JB-1 significantly attenuated
deficits in rearing (F1, 14 = 6.888, p = 0.02) (Fig. 2f). Over-
all, there was no main effect of treatment on rearing or
locomotion. Neither stress exposure nor treatment influ-
enced time spent in the center of the open field (Add-
itional file 1: Figure S1B). On the LDT, both defeated
groups exhibited fewer transitions into the light compart-
ment (F1, 57 = 36.34, p < 0.0001), which is a more salient
measure of anxiety-like behaviour [29] (Fig. 2 g). How-
ever, DEF/JB-1 mice ventured into the light compart-
ment more frequently than DEF/VEH mice, indicating
an anxiolytic-like effect of JB-1 administration (stress
exposure × treatment interaction [F1, 57 = 5.171, p = 0.027,
post hoc, p < 0.05]). Neither stress nor treatment affected
time spent in the light compartment (Additional file 3:
Figure S1C).
Given the paucity of literature regarding the long-term
ramifications on behaviour following cessation of inter-
ventions, we re-tested a subset of mice 3 weeks follow-
ing CSD exposure and treatment cessation. Entries into
the light compartment 24 h following the final defeat
were significantly different between the CON/VEH and
DEF/VEH groups, but not between the CON/VEH and
DEF/JB-1 or DEF/VEH and DEF/JB-1 groups (F1, 26 =
6.738, p = 0.004, post hoc, CON/VEH versus DEF/VEH
at 24 h, p < 0.01), further corroborating the anxiolytic-
like effects of JB-1 (Fig. 2 h). Three weeks post-stressor,
there were no significant differences between any of the
three groups, indicating a recovery of stress-induced
anxiety-like behaviour. Neither JB-1 nor time influenced
aggressor avoidance behaviour 3 weeks post-stressor
(Fig. 2i).
To investigate the neural mechanisms underlying the
effect of microbial treatment on the expression of stress-
related behaviours, we examined changes in expression
of genes related to the stress circuitry in the frontal cor-
tex and hippocampus. Neither stress nor treatment al-
tered the expression of corticotropin-releasing factor
receptor type 1 or type 2 in the frontal cortex or the
hippocampus, or the glucocorticoid receptor in the
frontal cortex (Additional file 4: Figure S2A–E). Stress
decreased the expression of glucocorticoid receptors in
the hippocampus (F1, 16 = 10.67, p = 0.005)—an effect
that was not influenced by JB-1 treatment (Additional
file 4: Figure S2F). Given that we have previously demon-
strated the effects of JB-1 administration on central
gamma-aminobutyric acid (GABA) receptors [10], we ex-
amined whether similar changes might underlie the effects
of the bacteria in a chronic stress model. Stress reduced
the expression of GABAAα2 (F1, 30 = 6.126, p = 0.019) and
GABAB1b mRNA (F1, 30 = 5.961, p = 0.021) in the frontal
cortex, in the absence of a treatment effect (Additional file
4: Figure S2G, H). There were no effects of either stress or
treatment on GABAAα2 or GABAAα2 mRNA levels in the
hippocampus (Additional file 4: Figure S2I, J).
These data demonstrate that microbial treatment
partially corrects the adverse effects of stress on social
preference, exploration, and anxiety-like behaviours.
Microbial treatment regulates stress-induced alterations
in the immune phenotype
The immune system represents an important interface
for bacteria-host signalling and has been hypothesized as
a potential effector of gut-brain communication [7, 15].
CSD increased the population of IL-10+ CD4+ CD25+
T cells (CD3+) (F1, 16 = 6.114, p = 0.025) (Fig. 3a).
Microbial treatment alone similarly increased the popu-
lation of these spleen-derived IL-10-expressing Tregs









Fig. 2 (See legend on next page.)
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(F1, 16 = 5.621, p = 0.031). The immunomodulatory ef-
fects of JB-1 were not limited to adaptive immunity, as
treatment also prevented the stress-induced increase in
spleen-derived dendritic cells (MHCII+ CD11c+)
expressing markers of activation, CD80 (stress expos-
ure × treatment interaction [F1, 15 = 8.224, p = 0.012, post
hoc, p < 0.05]) and CD86, though the latter did not reach
statistical significance (Fig. 3b, c).
This suggests that administration of JB-1 promoted
systemic changes in the immunoregulatory phenotype
and influenced the effects of chronic stress on host
immunity.
Microbial treatment does not prevent stress-induced
dysbiosis of the microbiota
Multiple groups have confirmed that stress induces dys-
biosis [12, 13, 30], correction of which can impart posi-
tive effects on the host [31, 32]. Thus, we investigated
whether JB-1 exerted its neurobehavioural effects on the
stressed host by restoring the microbiota.
Prior to social defeat, although significantly greater
levels of L. rhamnosus cells per gram of faeces were
detected in mice administered JB-1 (Additional file 3:
Figure S1D), JB-1 did not significantly alter the overall
profile of the microbial community (Additional file 3:
Figure S1E) or post-defeat body weight across groups.
As previously described [13], exposure to CSD re-
duced the diversity (F1, 68 = 13.21, p = 0.0005) and
richness (F1, 68 = 12.50, p = 0.0007) of the microbiota
(Fig. 4a). These alterations were not ameliorated in
DEF/JB-1 mice (post hoc, p > 0.05). Assessment of
community richness did reveal a significant stress expos-
ure × treatment interaction: CON/JB-1 mice had a richer
gut microbiota relative to CON/VEH mice (F1, 68 = 5.616,
p = 0.021, post hoc, p < 0.05). However, there was no effect
of treatment in the defeated groups (post hoc, p > 0.05).
To compare group differences in the overall micro-
biota profile, Bray-Curtis distances (Fig. 4b) were ana-
lysed using a priori planned comparisons. Stress altered
the microbiota profile: distances within non-defeated
mice were smaller than distances between defeated and
non-defeated mice (Fig. 4c; Additional file 2: Table S1;
Bonferroni-corrected non-parametric p = 0.013). JB-1
treatment did not prevent stress-induced changes in the
microbiota: profiles within a group (within-DEF/VEH
and within-DEF/JB-1) were not significantly closer than
profiles from the opposing group (DEF/VEH versus
DEF/JB-1), indicating a lack of clustering due to treat-
ment (Bonferroni-corrected non-parametric p > 0.05).
Moreover, JB-1- and vehicle-treated non-defeated mice
formed a separate cluster from DEF/JB-1 mice (Bonfer-
roni-corrected non-parametric p = 0.013).
We investigated whether microbial treatment restored
the relative abundance of specific OTUs that discrimi-
nated defeated mice from the non-defeated controls.
Eighteen OTUs (11 Bacteroidetes, 6 Firmicutes, 1 Pro-
teobacteria) were altered by stress exposure (q < 0.05)
(Additional file 2: Table S2), none of which were re-
stored by JB-1 treatment.
Alterations in the major microbial phyla—Firmicutes
and Bacteroidetes—are associated with dysbiosis and
disease [33–36]. However, there was no effect of treat-
ment on the Bacteroidetes/Firmicutes ratio (Fig. 4d).
Together, these data suggest that JB-1 treatment failed
to prevent stress-induced alterations to the microbiota
community.
Stress-induced dysbiosis persists for at least 3 weeks
There is growing evidence from human reports indicat-
ing co-morbidity between psychiatric conditions such as
depression and post-traumatic stress disorder (PTSD)
and gastrointestinal disorders, which are associated with
persistent dysbiosis [37]. Thus, 3 weeks following the
cessation of CSD, we examined the endurance of stress-
induced microbial disruptions and the possibility of
whether treatment facilitated recovery.
Group differences due to stress exposure were still evi-
dent at this time point (analysis of similarities [ANO-
SIM], R = 0.1307, p = 0.009). Within-group distances in
CON/VEH were smaller than the distances versus DEF/
VEH mice, indicating separation of CON/VEH and
DEF/VEH groups due to stress exposure (Fig. 4e;
Additional file 3: Figure S1F; Additional file 2: Table S1
[Bonferroni-corrected non-parametric p = 0.022]). There
(See figure on previous page.)
Fig. 2 Chronic stress induces deficits in social and anxiety-like behaviours in mice that are partially corrected by microbial treatment. a Microbial
treatment does not alter baseline sociability, measured by time spent in the social and non-social chambers, in vehicle-treated (n = 10) versus
JB-1-treated (n = 8) unstressed mice. b Vehicle-treated defeated mice (n = 15) exhibit avoidance of the social chamber—deficits that are corrected
in defeated mice treated with JB-1 (n = 10). c Data demonstrating the time spent in the social and non-social chambers as a log ratio across all
four groups. d Aggressor approach-avoidance test paradigm. e Socially defeated mice exhibit avoidance of a novel aggressor, independent of
treatment. f Chronic stress reduced rearing behaviour on the OFT, but was partially rescued by JB-1 treatment (n: CON/VEH = 29, CON/JB-1 = 13,
DEF/VEH = 27, DEF/JB-1 = 16). g Chronic stress reduced the number of entries into the light zone on the LDT, but was partially rescued by JB-1
treatment (n: CON/VEH = 18, CON/JB-1 = 12, DEF/VEH = 15, DEF/JB-1 = 16). h Anxiety-like behaviour across time, as measured by the number of
entries into the light zone, at 24 h and at 3 weeks following cessation of CSD treatment (n: CON/VEH = 11, DEF/VEH = 9, DEF/JB-1 = 9). i Avoidance
behaviour on the aggressor approach-avoidance test, at 24 h and at 3 weeks following cessation of CSD treatment (n: DEF/SAL = 9, DEF/JB-1 = 10).
*p < 0.05, **p <0.01, and ***p < 0.001. Data are represented as mean ± SEM
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was no statistically significant difference between ve-
hicle- and JB-1-treated defeated mice.
Similarly, comparison of community diversity and
richness at the 3-week time point indicated differ-
ences only between the CON/VEH and DEF/VEH
groups (Fig. 4f, phylogenetic diversity, F2, 28 = 7.893,
p = 0.002; Chao1 richness, F2, 28 = 6.061, p = 0.007).
Thus, these data indicate that social defeat-induced
dysbiosis persisted for at least 3 weeks following
stress exposure and the defeat-induced change in






Fig. 3 Effect of chronic social defeat stress and JB-1 treatment on splenocyte phenotype (n = 5/group). a IL-10+ CD4+ CD25+ T cells in mice
following exposure to chronic social defeat and JB-1 treatment. b JB-1 treatment prevents the stress-induced increase in CD80+ MHCII+ CD11c +
splenocyte levels in defeated mice c CD86+ MHCII+ CD11c + splenocytes in mice following exposure to chronic social defeat and JB-1 treatment.
d Fluorescence-activated cell sorting (FACS) gating strategy for IL-10+ CD4+ CD25+ T cells (CD3+). e FACS gating strategy for CD80+ and CD86+
on MHCII+ DCs (CD11c+). *p < 0.05. Data are represented as mean ± SEM





Fig. 4 JB-1 treatment does not affect stress-induced structural changes in the microbiota community. a Effect of chronic social defeat and JB-1
treatment on phylogenetic diversity and Chao1 richness estimates from the rarefied 16S rRNA data (n: CON/VEH = 18, CON/JB-1 = 13, DEF/VEH = 24,
DEF/JB-1 = 17, 7923 reads/sample). b, c Principle coordinates analysis (PCoA) of Bray-Curtis distances from the average rarefied 16S rRNA data (n: CON/
VEH = 18, CON/JB-1 = 13, DEF/VEH = 24, DEF/JB-1 = 17; n = 999 rarefactions, 6339 reads/sample) indicate a significant effect of social defeat on group
clustering (p = 0.013), but no effect of JB-1 treatment (median ±min/max). d Effect of chronic social defeat and JB-1 treatment on the taxonomic
distribution of OTUs at the phylum level (n = 17–24/group). e Bray-Curtis distances from the average rarefied 16S rRNA data (n = 999 rarefactions,
44,648 reads/sample) three weeks after stressor and treatment cessation indicate a persistent significant effect of social defeat on group clustering
(p = 0.022), but no difference between the control group and defeated mice treated with JB-1 (median ±min/max). f Phylogenetic diversity and Chao1
richness estimates from the rarefied 16S rRNA data (55,810 reads/sample) 3 weeks after stressor and treatment cessation indicate a persistent significant
effect of social defeat, but no difference between the control group and defeated mice treated with JB-1 (n = 9–11/group). *p < 0.05, **p <0.01, and
***p < 0.001. Data are represented as mean ± SEM unless otherwise indicated
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The faecal metabolome is altered by exposure to chronic
psychosocial stress and L. rhamnosus JB-1 treatment
Host and microbial metabolites play a contributory role
in health and disease, including neural development and
behaviour [16]. A total of 621 metabolites were detected
in the faeces of mice; 70 were significantly altered by
stress exposure (q < 0.1), many of which were associated
with pathways previously predicted using in silico tech-
niques: synthesis and metabolism of fatty acids, and
tryptophan and tyrosine metabolism (Additional file 2:
Table S3) [13]. Furthermore, 75 faecal metabolites were
regulated by JB-1 treatment (Additional file 2: Table S4).
Previous work has demonstrated that JB-1 signals the
brain via the vagus nerve [10, 22, 38]. To investigate sig-
nals that play a role in JB-1-driven vagal signalling, we
explored for metabolites that were elevated exclusively
in JB-1-treated stressed mice; however, no such metabo-
lites were detected (q < 0.1).
We investigated functional pathways that were altered by
exposure to CSD, but not in JB-1-treated mice. This criter-
ion (q < 0.1) yielded 15 metabolites (Fig. 5a, b; Additional
file 2: Table S5), including 1-methylnicotinamide—a
vitamin B3 derivative with anti-inflammatory effects
[39]—and 4-hydroxybutryrate (GHB), a metabolite with
neurotransmitter-like effects [40–42]. Other metabolites
meeting this criterion include glutarate, N-acetylcitrulline,
glycerate, lactobionate, 3-hydroxybutyrylcarnitine, 10-
hydroxystearate, multiple metabolites derived from
sphingolipid metabolism, alpha-muricholate, and lithocho-
late. However only for one metabolite that met this criteria,
tyramine, a monoamine with sympathomimetic properties
[43, 44], did the difference between DEF/VEH and DEF/
JB-1 reach statistical significance (Fig. 5c).
Stress increased the levels of kynurenine in both
groups of defeated mice (F1, 31 = 5.839, p = 0.022)
(Fig. 5d). Planned post hoc analysis revealed significant
differences between vehicle-treated defeated and control
groups (p < 0.05) but none between JB-1-treated control
and defeated mice (p > 0.05). Neither stress nor micro-
bial treatment affected the kynurenine/tryptophan
ratio—a sensitive estimate of cellular immunity [45, 46].
These data demonstrate that CSD alters the levels of
various faecal metabolites, some of which possess immu-
nomodulatory and neuroactive properties, and that JB-1
treatment may modulate some of these changes.
Discussion
Using a validated model of chronic stress and depression
[18, 19], we demonstrate, for the first time, the influence
of a single orally administered bacteria strain, Lactoba-
cillus rhamnosus JB-1, on behavioural deficits and
systemic immune alterations caused by chronic exposure
to a psychosocial stressor. While we observed no effects
on baseline behaviour, JB-1 attenuated stress-induced
behavioural deficits, including changes in sociability and
anxiety-like behaviour, and prevented immunoregulatory
alterations associated with the stress phenotype. Notably,
the tempering of stress-induced changes occurred in the
absence of any effects of treatment on stress-related dis-
ruptions in the microbiota, suggesting that JB-1 directly
Fig. 5 Effect of chronic stress and JB-1 treatment on the faecal metabolome. a–d Metabolites whose levels were altered by chronic stress but
prevented in JB-1-treated mice (n: CON/VEH = 10, CON/JB-1 = 5, DEF/VEH = 10, DEF/JB-1 = 10). a 1-methylnicotinamide, b 4-hydroxybutryrate,
c tyramine, d kynurenine. *p < 0.05, **p <0.01. Data are represented as median ±min/max
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modulates gut-brain signalling pathways independently
of the microbial community.
Following CSD, JB-1-treated stressed mice, as opposed
to vehicle-treated, did not show avoidance of novel so-
cial stimuli, exhibited more frequent rearing behaviour
in the OFT, and showed reduced aversion towards the
light chamber (LDT). These data support the emerging
literature suggesting that administration of specific
bacterial strains decreases anxiety- and depressive-like
behaviours [9, 10]. Indeed, we have previously demon-
strated that chronic administration of JB-1 in Balb/c
mice altered baseline levels of anxiety-like behaviour
[10]. That the effects of JB-1 here were limited to deficits
produced by chronic stress and not baseline behaviour
(Fig. 2), may be indicative of intrinsic differences
between Balb/c and C57BL/6 mice, the latter of which
exhibit reduced apprehension, neophobia, and anxiety-
like behaviour on baseline behavioural assays [47]. These
mouse strain-specific effects may have implications for
translational studies in humans, suggesting that, in keep-
ing with a recent report [48], JB-1 would not be ex-
pected to have an anxiolytic effect in non-anxious
individuals. Similarly, anti-depressants have very limited
effects on healthy subjects [49].
In models of psychiatric conditions, repeated aggres-
sion and defeat lead to persistent conditioned submissive
behaviour and aversion towards social stimuli [18, 50].
These behavioural manifestations bear similarity to
symptoms of social withdrawal in depression and phobic
avoidance of trauma-related stimuli in PTSD [51]. It is
notable that the ameliorating effects of JB-1 on deficits
in social behaviour were limited to interactions involving
a non-threatening conspecific, while avoidance of the
novel trauma-related stimulus was maintained. Previous
research has suggested dissociation of social and non-
social forms of anxiety-like behaviour [52]. For instance,
treatment with a human commensal organism, Bacter-
oides fragilis, in a model of autism spectrum disorder at-
tenuated deficits in anxiety-like behaviour, but did not
affect sociability [31]. Our findings suggest that social
anxiety may be further dissociated into discrete, differen-
tially modulated behaviours expressed towards non-
threatening versus threatening stimuli, the latter of
which is experience-dependent [18, 19]. Thus, the dis-
parate effects of JB-1 on behaviours expressed by
defeated mice may be due to independent underlying
neural circuitry. Such dissociable circuitry has been indi-
cated by work on the stimulation of nucleus accumbens
afferents, which alters behaviour towards a novel aggres-
sor, but not anxiety-like behaviour [27]. This concept is
further supported and emphasized in the current study
given the recovery of anxiety-like behaviour but not of
aggressor avoidance behaviour 3 weeks post-defeat
(Fig. 2 h, i). In addressing neural mechanisms underlying
the effect of microbial treatment on the expression of
stress-related behaviours, we examined a limited number
of genes related to the stress circuitry in the frontal cor-
tex and hippocampus. While stress exposure reduced
GABA receptor expression in the prefrontal cortex
and glucocorticoid receptor expression in the hippo-
campus, there was no effect of microbe treatment on
these measures. This contrasts the previously demon-
strated effects of JB-1 administration on baseline
expression of central GABA receptors in Balb/c mice
[10]. While these results further emphasize the
mouse strain-dependent effects of microbe exposure
on gut-brain signalling, a more extensive assessment
of additional neural pathways in multiple brain re-
gions will be required to identify potential circuitry
involved in JB-1-induced attenuation of stress-related
behaviour.
Consistent with the immunomodulatory role of gut
bacteria [15] and previous studies with JB-1 [24], micro-
bial treatment influenced systemic changes in the CSD-
induced immune phenotype. Social defeat increased the
population of activated splenic DCs—a shift completely
prevented by JB-1. Furthermore, treatment with the bac-
teria induced systemic expansion of Treg: a population
that produces high levels of the anti-inflammatory cyto-
kine, IL-10 [53]. Coordination between multiple host
systems—and dysregulation thereof—likely contributes
to the phenotypic changes in stress and related psychi-
atric conditions, during which systemic disruptions and
allostatic load accumulate over extended periods of time.
For instance, a pro-inflammatory milieu and a decrease
in Tregs are commonly observed in severe stress and
PTSD [17, 54] and form the central premise of the in-
flammation theory of depression [55]. Indeed, stress-
induced trafficking of peripheral monocytes to the brain
appears to play a crucial role in anxiety-like behaviour
[56]. Disruption of the host-microbiota relationship dur-
ing chronic stress may contribute to exaggerated inflam-
mation and immune dysregulation and is associated with
colitis and inflammatory bowel disease [11, 57]. The ob-
served acute increase in the Treg population (Fig. 3a)
[13] following stress may be a counteractive response to
the pro-inflammatory shifts described in the literature
upon stress induction [13, 56, 58]; such responses are a
well-documented reaction to host inflammation in an at-
tempt to restore homeostasis [59]. Although this natural
allostatic mechanism does not prevent an inflammatory
environment during maladaptive stress, JB-1-induced
modulation of host-initiated immunoregulatory re-
sponses may be one mechanism contributing to the be-
havioural effects of the bacteria. Similar mechanisms
were posited to explain the stress-mitigating effects of
Mycobacterium vaccae immunization, which were dem-
onstrated to depend on Tregs [11]. These data suggest
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that recruitment of immune pathways in bottom-up
(gut-to-brain) signalling is important. The current study
was limited to two immune cell lineages: dendritic cells
and T cells. Clearly, additional immune cell types may
make important contributions to gut-brain signalling.
Future studies should include a broader assessment of
the immune system and more detailed examination of
microbiota-immune-neural coordination and dysregula-
tion of these systems in stress.
It has been proposed widely that modifying the resi-
dent intestinal bacteria in disease can reverse microbial
dysbiosis and restore homeostatic function [60, 61]. Such
an approach is especially relevant given evidence of
microbiota disruption in severe stress and psychiatric
conditions and its association with adverse gastrointes-
tinal outcomes [37]. Thus, we investigated whether the
improved neurobehavioural phenotype due to microbial
treatment was associated with alterations to the existing
microbiota community. Prior to stress exposure, admin-
istration of JB-1 did not alter the profile of the microbio-
ta—data that parallel observations in humans who were
administered a different strain of L. rhamnosus [62]. Fur-
thermore, in our study, microbial treatment did not pre-
vent any of the shifts in the microbiota community due
to stress exposure. JB-1 treatment also completely failed
to restore the diversity and richness of the microbiota or
correct the relative abundances of specific OTUs altered
by stress. Thus, the neuroactive properties of the benefi-
cial microbe may be mediated independently of restoring
microbial community balance, and might be dependent
on its functional activity and direct modulation of host
signalling pathways.
Not unexpectedly, the stress-induced dybiosis was ac-
companied by a significant change in levels of various
faecal metabolites, while, perhaps more surprisingly, JB-
1 treatment alone significantly modulated the levels of
75 metabolites, many of which have immunomodulatory
and neuroactive properties. While the source of these
metabolites, host or microbe, cannot be identified, these
observations suggest that JB-1 could alter the function
of the existing gut microbiota without influencing com-
position. Most notably, the reduction in tyramine levels
induced by CSD was the only metabolite change signifi-
cantly inhibited by JB-1 treatment. Tyramine is a mono-
aminergic neuromodulator, acting as an agonist for trace
amine-associated receptor 1 (TAAR1) [63]. Tyramine
also causes the release of norepinephrine from sympa-
thetic nerves, reversing re-uptake through the norepin-
ephrine transporter and has been demonstrated to
induce serotonin (5-HT) production by enterochromaf-
fin cells [64]. Given that intestinal 5-HT [65] and cate-
cholamines [66] have been proposed as mediators of
microbe-gut-brain signalling via modulation of the en-
teric nervous system, the impact of luminal tyramine
levels on the gut-brain axis may warrant further investi-
gation. The current study focused on faecal metabolites,
with the understanding that gut lumen metabolites act-
ing at the level of the gut epithelium, enteroendocrine
cells, and enteric nervous system may play a role in
microbe-gut-brain signalling. However, future assess-
ment of plasma metabolites may identify circulating fac-
tors, produced by gut microbes or induced in the host,
which have more direct effects on the central nervous
system.
One limitation of the current study is that we only
assessed the faecal microbiota, and it is possible that JB-
1 stabilized site-specific microbiota, for example, in the
small intestine or specifically associated with the epithe-
lium elsewhere, that are involved in gut-brain signalling.
However, a direct action of JB-1 on gut-brain signalling
is further supported by previous studies using in vivo
and ex vivo models, demonstrating that it can directly or
indirectly activate the vagus nerve and that an intact
vagus is required to mediate the effects of this bacter-
ium, at least on the baseline behaviour of Balb/c mice
[22]. Collectively, these data suggest that JB-1, independ-
ently of changes in the microbiota, can recruit host
signalling pathways, likely including vagal afferents that
mediate the effects of the bacteria on severe CSD-
induced neurobehavioural changes. Investigation of the
role of the vagus in mediating microbe-induced modula-
tion of behaviour in the CSD model is certainly
warranted.
Although numerous studies have demonstrated the ef-
fect of environmental adversity on disruption of gut
microbiota [11–13], there is very little evidence on the
permanence of these changes in stress-related disorders
or on whether microbial supplementation can facilitate
the recovery of dysbiosis. A limited number of observa-
tions suggest a complex relationship between environ-
mental factors and perturbations of the gut microbiota.
Certain factors impart transient changes in the commu-
nity, while others, for instance, antibiotic usage, leave be-
hind a more persistent signature [67, 68]. Furthermore,
factors such as birth delivery mode have marked effects
on the microbiota community during early life that
are no longer distinguishable in adulthood [69]. Our
own observations suggest that stress-induced disrup-
tions in the microbiota appear stable for a prolonged
period following stress exposure. Examination of
defeated mice 3 weeks following CSD revealed en-
during structural changes in the faecal microbial
community: defeated mice continued to show re-
duced diversity and richness in the variety of species
represented while exhibiting broad-scale changes in
overall composition and profile. The long-term stress-
induced changes in the microbiome were not significantly
altered with JB-1 treatment.
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Conclusions
There have been increasing efforts to understand how
large-scale disruptions and dynamic shifts in gut
microbiota can drive phenotypic changes and disease
states [70]. This study represents a series of findings
that further clarify the role of gut bacteria on neural
function and behaviour. Although there continue to
exist major gaps in our understanding of how disrup-
tions in the microbiota contribute to neuropsychiatric
conditions, the emerging theme underscores the
intricate interactions between these systems in health
and disease. While the current study did not delin-
eate a mechanism of action of JB-1 in attenuating
stress-induced behavioural changes, the results sug-
gest that a more detailed investigation of immunomo-
dulation and neural circuitry will likely provide
valuable mechanistic insights. Furthermore, despite
the complexity of the observed structural and func-
tional changes in the microbial consortia, our data
indicate that restoration of homeostasis can be facili-
tated using a single microbial strain. Given the
diversity and inter-individual variability of the human
gut microbiome [71–73], we propose that microbial-
based interventions that bypass the microbiota to
directly affect the host may possess greater thera-
peutic potential for the effective treatment of psychi-
atric conditions, or as an adjunct to current
approaches.
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